Foamix (FOMX) R&D Day Offers 3 New Products - Cantor

Cantor Fitzgerald analyst, Louise Chen, reiterated her Overweight rating on shares of Foamix Pharmaceuticals (NASDAQ: FOMX) after FOMX hosted a well-attended and upbeat R&D day to review its prelaunch medical affairs, commercial strategy and clinical data for FMX101 (acne) and FMX103 (papulopustular rosacea).

The analyst stated "The company also disclosed three new products that target large unmet needs in dermatology. FOMX said that it would consider business development opportunities, but would be mindful of its existing cash position. Finally, we think the company will continue to build out its medical dermatology business and explore opportunities in aesthetics as well".

No change to the price target of $15.

For an analyst ratings summary and ratings history on Foamix Pharmaceuticals click here. For more ratings news on Foamix Pharmaceuticals click here.

Shares of Foamix Pharmaceuticals closed at $3.66 yesterday.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral